FRX Forest Road Acquisition Corp

Forest Laboratories, Inc. (NYSE: FRX) (“Forest”) today announced that IVS Associates, Inc., the independent inspector of elections, has certified the final voting results for the Company’s Annual Meeting, which was held on August 18, 2011. The certified results, which are consistent with the preliminary results announced on August 22, 2011, confirm that each of the ten Company nominees was elected to the Forest Board of Directors by a substantial margin. Forest’s ten directors are: Nesli Basgoz, M.D.; Christopher J. Coughlin; Dan L. Goldwasser; Kenneth E. Goodman; Gerald M. Lieberman; Lawrence S. Olanoff, M.D., Ph.D.; Lester B. Salans, M.D.; Brenton L. Saunders; Howard Solomon; and Peter J. Zimetbaum, M.D.

As previously disclosed, more than 226 million votes, or approximately 98% of the votes cast in the election, were voted for each of the six Forest nominees that had not been contested. The four directors running for contested seats were also elected by wide margins. Mr. Goodman and Mr. Solomon received more than 169 million and 165 million votes, respectively, and Messrs. Goldwasser and Salans each received over 152 million votes for their election.

In addition, the certified results confirm that Forest shareholders approved the advisory vote on executive compensation, supported an annual frequency for the advisory vote on executive compensation, and ratified the appointment of BDO USA, LLP as the Company’s independent registered public accountants.

Howard Solomon, Chairman and Chief Executive Officer of Forest, stated, “On behalf of the entire Board, I wish to thank our shareholders for their support. I look forward to working with the highly qualified group of directors we have assembled to continue building and delivering value for Forest’s shareholders.”

The certified results were as follows:

Election of Directors     For     Withheld  

Forest Nominees:

    Howard Solomon 165,349,211 4,623,743 Nesli Basgoz, M.D. 227,451,746 3,615,456 Christopher J. Coughlin 226,635,822 4,431,380 Dan L. Goldwasser 152,002,769 1,617,812 Kenneth E. Goodman 169,301,063 671,891 Gerald M. Lieberman 227,425,851 3,641,351 Lawrence S. Olanoff 226,222,145 4,845,057 Lester B. Salans 152,935,444 685,137 Brenton L. Saunders 227,430,702 3,636,500 Peter J. Zimetbaum 227,436,483 3,630,719  

Icahn Nominees:

    Alexander J. Denner 48,928,220 28,518,401 Richard Mulligan 70,539,256 6,907,365 Lucian A. Bebchuk 42,126,141 1,968,107 Eric J. Ende 33,485,948 27,608,300 Advisory Vote on Executive Compensation For     Against     Abstain

170,391,984

59,879,803 795,426 Frequency of Advisory Vote on Executive Compensation 1 Year     2 Years     3 years     Abstain 213,927,107 748,048 15,498,879 893,078 Auditor Ratification For     Against     Abstain 229,586,578 1,466,628 629,430

Forward Looking Information

Except for the historical information contained herein, this document contains forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. These statements involve a number of risks and uncertainties, including the difficulty of predicting FDA approvals, the acceptance and demand for new pharmaceutical products, the impact of competitive products and pricing, the timely development and launch of new products, changes in laws and regulations affecting the healthcare industry and the risk factors listed from time to time in Forest Laboratories’ Annual Reports on Form 10-K (including the Annual Report on Form 10-K for the fiscal year ended March 31, 2011), Quarterly Reports on Form 10-Q, and any subsequent SEC filings.